PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.\', \'Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.\', \'Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.\', \'Clinical Division of Infectious Diseases, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.\', \'Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.\', \'HIV/AIDS Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.\', \'Scientific Direction, National Institute for Infectious Disease \'Lazzaro Spallanzani\'-IRCCS, Rome, Italy.\', \'Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.\', \'Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0163-4453(21)00094-310.1016/j.jinf.2021.02.023
?:hasPublicationType
?:journal
  • The Journal of infection
is ?:pmid of
?:pmid
?:pmid
  • 33639176
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all